

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12P 21/08, C12N 5/16 G01N 33/53, 33/577	A2	(11) International Publication Number: WO 90/10709 (43) International Publication Date: 20 September 1990 (20.09.90)
(21) International Application Number: PCT/US90/01401		(74) Agents: HAMRE, Curtis, B. et al.; Merchant, Gould, Smith, Edell, Welter & Schmidt, 3100 Norwest Center, 90 South Seventh Street, Minneapolis, MN 55402 (US).
(22) International Filing Date: 14 March 1990 (14.03.90)		
(30) Priority data: 324,392 14 March 1989 (14.03.89) US		(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK, DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), HU, IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent), SU.
(71) Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA [US/US]; Varner Hall, 3835 Holdrege Street, Lincoln, NB 68503 (US).		
(72) Inventors: WAGNER, Fred, W. ; Route 1, Box 77B, Walton, NB 68461 (US). WYLIE, Dwane, E. ; 1965 Brower Road, Lincoln, NB 68502 (US). SCHUSTER, Sheldon, M. ; 910 Southwest 112th Street, Gainesville, FL 32607 (US). COOLIDGE, Thomas, R. ; Beebe Hill Road, Falls Village, CT 06031 (US). SONG, Pill-Sooon ; 5930 Woodstock, Lincoln, NB 68512 (US). PARKER, William ; 1020 East Street, Apt. E, Lincoln, NB 68508 (US).		Published <i>Without international search report and to be republished upon receipt of that report.</i>

(54) Title: MONOCLONAL ANTIBODIES FOR SMALL MOIETIES, METHODS THEREFOR

INHIBITION OF 1F10 BY HG AND MG



(57) Abstract

The invention is directed to monoclonal antibodies, their fragments, single chains and polypeptide mimics of their hyper-variable regions which immunoreact with bare small moieties such as metallic cations and small organic molecules, the hybridomas for production of the monoclonal antibodies, immunogen compounds for developing the hybridomas, and methods for use of the monoclonal antibodies.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT Austria	ES Spain	MG Madagascar
AU Australia	FI Finland	ML Mali
BB Barbados	FR France	MR Mauritania
BE Belgium	GA Gabon	MW Malawi
BF Burkina Faso	GB United Kingdom	NL Netherlands
BG Bulgaria	HU Hungary	NO Norway
BJ Benin	IT Italy	RO Romania
BR Brazil	JP Japan	SD Sudan
CA Canada	KP Democratic People's Republic of Korea	SE Sweden
CF Central African Republic	KR Republic of Korea	SN Senegal
CG Congo	LK Liechtenstein	SU Soviet Union
CH Switzerland	LK Sri Lanka	TD Chad
CM Cameroon	LU Luxembourg	TG Togo
DE Germany, Federal Republic of	MC Monaco	US United States of America
DK Denmark		

MONOCLONAL ANTIBODIES FOR SMALL
MOIETIES, METHODS THEREFOR

Cross-Reference to Related Applications

This is a continuation-in-part of U.S.

5 Application Serial No. 07/324,392, filed March 14, 1989.

Technical Field

This invention relates to: novel methods for detecting, removing, neutralizing or adding minute 10 quantities of small moieties such as metallic cations and small organic molecules; monoclonal antibodies or fragments thereof that are immunoreactive with the small moieties; and hybridomas and other methods for production of the monoclonal antibodies or fragments 15 thereof.

Background of the Invention

Small chemical moieties can and often do affect the environment and biological systems. These effects 20 become astounding when it is realized that minute quantities of small moieties are involved. Moreover, the presence or absence of low concentrations of small moieties in the environment can have long term consequences. Lead in water and gasoline bear witness. 25 Minute quantities of metallic cations and small organic molecules can regulate, influence, change or toxify the environment or biological systems.

The detection, removal, addition or neutralization of such minute quantities constitutes a 30 focal point for continued research in many fields. For example, many efforts have been made to detect and remove minute, toxic amounts of heavy metal ions such as mercury from the environment. The efforts often have not been successful or economical for widespread 35 application. On the other hand, minute concentrations of other heavy metals are important for the proper function of biological organisms. Zinc, for example, plays a major role in wound healing. The function of magnesium in plant photosynthesis is another.

Small moieties also exhibit dual roles.

Mercury is used in diuretics, topical anti-bacterial agents, skin antiseptics, ointments, and in chemical manufacturing operations. Yet when ingested by mammals,
5 such as from drinking water, it is highly toxic in very small amounts. Hence, detection and quantification of minute concentrations of heavy metals in drinking water and other media would serve exploratory, safety and regulatory goals.

10 Small organic molecules such as cleaning fluids (e.g. trichloroethylene), as well as many pesticides and herbicides have small business, agricultural and industrial applications. The former are used in processing, formulating, cleaning and purifying while
15 the latter retard infestation by vermin, insects and undesired plants. However, these molecules also find their way into ground water and subsequently contaminate water used for consumption, agricultural and industrial purposes. Hence, efficient and accurate identification
20 of minute concentrations of small organic molecules in drinking water or other media would be an important step toward their control.

Cosmetic formulations, perfumes, and other proprietary products often contain minute levels of
25 certain small organic compounds. The appropriate selection and mixture of these compounds is the secret of the perfumer's art. Hence, determination of the concentrations and identities of these compounds could serve as a means for cosmetic control or for cosmetic
30 design.

Many foods contain minute quantities of small organic compounds. These compounds contribute to the flavor notes and odor of the foods. For example, ethyl butyrate and limonene contribute to the fresh flavor
35 notes so characteristic of freshly squeezed orange juice. Hence, determination of the concentrations and identities of such compounds within foods and the

isolation and purification of the same would help advance food design and screening.

- Removal of minute quantities of small moieties from biological or inanimate systems carries many implications. Sea water contains minute concentrations of gold and platinum. Economic removal and refining of these noble metals from sea water could be rewarding. Metal, in particular, lead poisoning has long had serious life-threatening and debilitating consequences.
- The ability to easily detect traces of toxic metals on site and in the field and to selectively remove toxic metals from fluids and tissues of children and other people, contaminated with trace amounts of such metals, should provide major steps in controlling and eliminating these problems. Finally, nuclear contaminants such as radioactive strontium, cobalt and others can endanger the population. Selective removal of these radioactive isotopes from the fluids and tissues of people so contaminated could avoid radiation sickness.

It would, therefore, be highly desirable to identify and control minute quantities of helpful or harmful small moieties in aqueous biological or inanimate systems. In most contexts, however, the detection, removal, addition or neutralization of small moieties is a difficult, time consuming, expensive and often unfeasible if not impossible task. Other compounds often mimic the small moieties and interference with measurements will result. Moreover, the detection methods employed today are usually not sufficiently sensitive at the minute quantities under consideration here. Consequently, it is desirable to develop reliable, quick and economic methods which can be used in the lab or the field for accurately identifying and controlling minute quantities of small moieties in aqueous systems.

Antibodies would seem to be uniquely suited for this task. Their high degree of specificity for a known antigen would avoid the interference caused by contaminants. Their sensitivity in the picomolar or 5 lower range would accurately and efficiently target and detect the minute levels.

Monoclonal antibodies, of course, come to mind as especially suited agents for practice of this technique. Since Kohler and Milstein published their 10 article on the use of somatic cell hybridization to produce monoclonal antibodies (Nature 256:495 (1974)), immunologists have developed many monoclonal antibodies which strongly and specifically immunoreact with antigens.

15 Notwithstanding this suggestion, the conventional understanding about immunology teaches that antibodies against small moieties cannot be developed. The mammal immunization step, which is key for the production of monoclonal antibodies, requires a molecule 20 that is large enough to cause antigenic reaction. Medium sized molecules (haptens), which are not of themselves immunogenic, can induce immune reaction by binding to an immunogenic carrier. Nevertheless, immunologists view small molecules such as metallic 25 cations and small organic molecules as not large or structurally complex enough to elicit an antibody response. One theory appears to hold that electron rich rings such as those associated with benzene and carbohydrates are needed at a minimum to cause 30 immunogenicity. V. Butler, S. Beiser, Adv. Immunol., 17, 255 (1973). The molecular size and complexity of an inorganic or organic small moiety is thought to be insufficient for eliciting an antibody response. To date, therefore, no monoclonal antibodies which 35 immunoreact with small moieties per se have been reported in the literature.

Several immunologists have reported production of monoclonal antibodies to metallic ion chelates. For example, in U.S. Patent No. 4,722,892, monoclonal antibodies are disclosed which immunoreact with a complex of a chelating agent, such as ethylene diamine tetracetate (EDTA), and a heavy metal such as indium. In EPO Patent Application 0235457, monoclonal antibodies that immunoreact with a chelate of gold cyanate and carbonate coating are disclosed. In these instances, however, the monoclonal antibodies bind with the metal chelate complex rather than the bare metallic ion itself. Disadvantages of these methods include: the complicated reagents involved in detection, lack of simple tests that discriminate among antigens, cross-reactivity with chelates of other antigens and cross-reactivity with the chelate itself.

Other instances of monoclonal antibody combinations with metals involve metal tags. The metal chelates are bound to the antibody at a site remote from the antigen binding site or sites. The metal or metal chelate is not the antigen. Instead, it is a tag to indicate the presence of the monoclonal antibody when it reacts with its specific antigen. See for example, V.P. Torchilian et al., Hybridoma, 6, 229 (1987); and C.F. Meares, Nuclear Medical Biology, 13, 311-318 (1986).

It is therefore, an object of the invention to develop monoclonal antibodies and fragments thereof that immunoreact with small moieties per se. It is another object of the invention to develop methods for detecting or neutralizing small moieties within, adding small moieties to, or removing small moieties from biological or inanimate systems through the use of the monoclonal antibodies and fragments thereof. Further objects include development of hybridomas which produce the monoclonal antibodies, development of immunogen compounds for generation of antibody reactivity to the small moieties and development of methods for production

of antibody fragments. Yet another object is the development of monoclonal antibodies and fragments thereof that are capable of discriminating very similar small moieties.

5

Summary of the Invention

These and other objects are achieved by the present invention which is directed to monoclonal antibodies and fragments thereof for immunoreaction with 10 small moieties. The invention is as well directed to hybridomas which produce the monoclonal antibodies, to immunogen compounds of the small moieties which cause development of the appropriate mammalian antibody response and to methods for producing antibody 15 fragments. The invention is further directed to methods for detecting, removing, adding, or neutralizing the small moieties in biological and inanimate systems through the use of the monoclonal antibodies or fragments thereof.

20 The advantages of the invention include among others: the lack of complication by additional reagents, a preference for a high binding constant with a group of small moieties having similar coordination chemistry and electron configuration and a lack of 25 cross-reactivity with other classes of antigenic materials and other classes of small moieties, an especial preference for a high binding constant with a particular small moiety and a lack of cross-reactivity with all other small moieties, and lack of cross- 30 reactivity with test reagents.

The monoclonal antibody and fragments thereof immunoreact with a small moiety per se. The state of the small moiety during this immunoreaction is one of non-coordination with any other substance; in other 35 words, in a preferred state it is bar or expos d. The monoclonal antibody or fragment thereof will also undergo immunoreaction with small moiety when it is in a

partially exposed stat as well. Preferably, the monoclonal antibody and fragments thereof exhibit high specificity toward a group of small moieties with similar coordination chemistry and electron configuration and little cross-reactivity for other classes of small moieties. Especially preferably, the monoclonal antibody and fragments thereof exhibit a substantially high degree of specific immunoreactivity toward a particular small moiety and little cross-reactivity with all other small moieties.

The monoclonal antibody or fragment shows a discrimination between a particular group or individual small moiety and other groups or other individual small moieties that constitutes at least about a 10^2 difference, preferably a 10^3 to 10^5 difference, in the respective dissociation constants. Preferably, the monoclonal antibody is a member of the immunoglobulin G, A or E classes and has an association constant for the small moiety that is about 10,000 fold greater than the association constant for the immunogen compound without the small moiety. When the monoclonal antibody displays immunospecificity for a particular member of a group of very similar small moieties, its relative association constant for such a particular small moiety will be about 10,000 fold greater than that for the other small moieties of such a group.

The invention includes as well fragments of the monoclonal antibody such as the F_{ab} , $F(ab)'$ fragments, and the individual heavy and light chains of the monoclonal antibody. Fragments and functional segments of the individual chains, especially the entire variable region fragment and segments thereof, and mimetic variable region segments of the monoclonal antibody (i.e., polypeptides having sequences which incorporate segments of the monoclonal antibody variable region or constitute variations of that variable region) are also contemplated.

The hybridoma of the invention, which produces the monoclonal antibody, is formed from immune cells that are sensitized toward the small moiety or class of similar small moieties. The formation is accomplished 5 by fusion of an immortal mammal cell line and mammal immune cells from a second mammal previously immunized with the immunogen compound which contains the small moiety. Selection of the appropriate hybridoma is determined by cross-screening the secreted monoclonal 10 antibody against the small moiety and against controls which incorporate the small moiety or very similar congeners.

Fragments of the monoclonal antibodies including F_{ab} , $F(ab)'$, the heavy and light chains and 15 fragments or segments thereof and mimetic variable region segments as well as the monoclonal antibodies themselves can be produced by recombinant cDNA techniques for generating plasmid libraries containing a repertoire of DNA sequences taken from the antibodies as 20 described in the following sections. Selection of the desired fragment or monoclonal antibody is accomplished by testing the expression products of the library of recombinant cells containing the recombinant expression vectors. The test involves assaying for immune reaction 25 between the expression product and an immunogen compound or a combination of antigen probe and the small moiety.

The immunogen compound of the invention is composed of a biopolymer carrier, a spacer arm covalently bonded to the carrier and the small moiety 30 which is coordinated or covalently bonded to the spacer arm. The spacer arm is semi-rigid and has at least one small moiety coordination site. This arrangement maintains the small moiety in at least a partially exposed state and prevents substantially complete 35 inclusion or chelation of the small moiety by spacer arm and/or carrier. Preferably, the spacer arm coordination with the small moiety is monodentate.

The biopolymer carrier may be a polysaccharide, a synthetic polyamide or preferably a protein.

Preferred classes include blood or tissue proteins.

The spacer arm is no more than about 25 atoms
5 in length. It is composed of one of three classes: an oligopeptide, an aliphatic compound or an aliphatic fragment. The first two are each substituted with no more than about 2 pendent Lewis acid or base groups, and a coupling group for forming a covalent bond with the
10 protein carrier. The latter is substituted by a coupling group for forming a covalent bond with the protein carrier, and a carboxylic acid, aldehyde, hydroxyl, mercapto, amine or other group adapted for carbon-carbon bonding with, or covalently bonded to, the
15 small moiety. For each class of spacer arm, the coupling group is an amine, carboxylic acid, aldehyde, hydroxyl or mercapto group. The latter class of spacer arm is appropriate when the small moiety is an organic compound.

20 A preferred spacer arm for metallic cations is an oligopeptide or aliphatic compound having no more than about 2 pendent Lewis base groups wherein the deformation of the electron shell of the Lewis base group is approximately of the same character as the
25 deformation of the electron shell of the metallic cation. Especially preferred Lewis base groups for transition elements and the heavy metals are those containing sulfur. Especially preferred are oligopeptides such as glutathione and cysteine, mercapto
30 ethanol amine, dithiothreitol, amines and peptides containing sulfur and the like.

The small moiety has a molecular size of no more than about 15 to 20 angstroms in length. Included are metallic cations and linear or branched aliphatic
35 organic molecules having a molecular size of no more than about 15 atoms in length. Organic small moieties having aromatic rings, especially non-electronegatively

substituted aromatic rings, can as well be detected, neutralized, added or removed according to the invention.

The metallic cations are derived from metals 5 such as aluminum, lithium, boron, gallium, galenium, arsenic, period four transition metals, and period five, six and seven metals, transition elements and inner transition elements. Metallic cations of special mention as the small moiety include those derived from 10 zinc, lead, cadmium, bismuth, cobalt, arsenic, chromium, copper, nickel, gold, silver, platinum, strontium and mercury.

Organic compounds of special mention as the small moiety include aliphatic compounds, linear organic 15 compounds, small peptides, saccharides, fats, linear organic compounds which may be substituted by polar groups, pesticides, herbicides, toxic halogenated organic compounds and aromatic compounds. The organic compounds, especially the aliphatic compounds, may be 20 optionally substituted by halogens and other groups such as esters, ethers, hydroxyls, amides, sulfides, sulfones, sulfates, sulfhydryls, nitros, nitriles and the like. The aromatic compounds may be substituted by groups such as esters, ethers, hydroxyls, amides and 25 sulfides.

The methods according to the invention utilize the monoclonal antibody or a fragment thereof for detection, removal, neutralization or addition of the small moiety respectively in, from, within or to a 30 liquid or gaseous medium. These methods utilize features such as monoclonal antibody or fragment immobilization, small moiety immobilization, competitive binding, means employing an oscillating probe, means for micromagnetic binding, anti-sera antibody for the 35 monoclonal antibody or fragment, enzyme tags, radioactive tags, spectrometric tags and other

physiochemical methods used to monitor antigen(i. . , small moiety)-antibody interactions.

Methods for detection that are based upon immobilization indicate the presence of the small

5 moiety-monoclonal antibody (or fragment thereof) complex by known immunologic assay techniques. In a step either before or after formation of the complex, the small moiety (or complex) may be coordinated with an immobilized antigen probe for the small moiety. The
10 antigen probe may be a spacer arm or a peptide or protein having a complexing group including a sulphhydryl, carboxyl, carbonyl, amino, hydroxyl or amide group or any combination thereof. When the probe formula is the same as the spacer arm formula, the probe
15 may be, but need not be, the same structure as the spacer arm of the immunogen compound used to develop the monoclonal antibody. The probe will hold the small moiety in at least a partially exposed state. Non-immobilized materials are then removed from the mixture
20 holding the immobilized probe-small moiety or immobilized probe-complex, and if the antibody or fragment has not been added, it is added at this point to form the immobilized probe-complex. Immunoassay completes the steps for this detection method.

25 Methods for detection that are based upon an immobilized monoclonal antibody or a fragment thereof utilize tagged substances that bind with monoclonal antibody, fragment or complex. A radioactive version of the small moiety or a similar tagged form thereof can
30 also be used. The tags include fluorescent, colorimetric, enzymatic, tagged general anti-sera antibodies for the monoclonal antibody or fragment, and other spectrally active groups that can be coordinated or bonded to the monoclonal antibody, fragment, complex
35 or small moiety. Preferred tags for the antibody include color producing enzymes and anti-animal species antibodies. A preferred tag for the small moiety is a

an antigen probe containing a spectrally active group. In a first step, the immobilized monoclonal antibody or a fragment thereof is combined with the medium suspected of containing the small moiety. After removal of the 5 non-immobilized components, an aliquot a tagged substance is added. It binds to immobilized complex and measurement of the tagged complex will determine the concentration of unknown small moiety.

Methods for detection that are based upon an 10 oscillating probe utilize either an immobilized probe for the small moiety or preferably immobilized monoclonal antibodies or fragments thereof. This method measures the change in frequency of an oscillating surface as a function of the change in weight of that 15 surface due to the binding of the non-immobilized small moiety or monoclonal antibody (or fragment thereof). In the preferred method the monoclonal antibodies or fragments thereof are immobilized on the surface of a high frequency oscillating probe. The probe is placed 20 into a medium containing an unknown quantity of small moiety. Binding of the small moiety to the immobilized monoclonal antibody or fragment thereof will change the oscillation frequency of the probe. Hence, the degree 25 of change will indicate the level of small moiety present.

When the small moiety is a metal ion in an aqueous medium, an especially preferred method for detection utilizes as the probe an oligopeptide having reactive sulphhydryl group(s) capable of coordinating 30 with the metal ions. The oligopeptide and the monoclonal antibody or fragment thereof specific for the metal ion unknown are added to the aqueous medium. The medium then is assayed for the presence of metal ion-monoclonal antibody (or fragment) complex. The 35 interaction of the antibody or fragment with the metal ion is independent of the order of addition of the

reactants and is independent of the identity of the oligopeptide.

In an especially preferred version of this method, a fixed support is utilized. Here, either the 5 oligopeptide or the monoclonal antibody (or fragment) is immobilized on the fixed support. The method is then conducted as related above.

The invention, in addition, contemplates methods for small moiety removal from, small moiety 10 neutralization within or small moiety addition to biological or inanimate systems. For all methods, an effective amount of the monoclonal antibody or fragment thereof is combined in some fashion with at least part of the system. Pursuant to the removal method, 15 immunoconjugated monoclonal antibody(or fragment)-small moiety is removed by separation means such as immunoprecipitation, immobilization, chromatography, filtration, magnetic attraction, photolytic binding, affinity binding and the like. Pursuant to the 20 neutralization method, the immunoconjugated monoclonal antibody(or fragment)-small moiety remains in the system until it is removed by non-specific means. Pursuant to the addition method, the immunoconjugated antibody(or fragment)-small moiety also remains in the system and 25 the small moiety is actively incorporated or otherwise used therein.

When the system treated in the foregoing methods is inanimate such as contaminated water or industrial waste, the monoclonal antibody or fragment 30 may be immobilized on a solid support or may be capable of binding, reacting or complexing with another substance that is immobilized or immobilizable. These steps encompass affinity binding of an enzyme or anti-sera antibody (for the monoclonal antibody) with the 35 monoclonal antibody or with a tag bound to the monoclonal antibody, magnetic particles through a tag containing iron, photolytic binding agents bound to the

- antibody such that photolysis will cause separation, and removal by binding or partition on a solid support especially as applied to any of the foregoing substances. Use of the probe in these instances is optional. This method is preferred as a means for removing heavy metals from aqueous environments.
- Removal of undesirable metals such as lead, mercury and cadmium as well as desirable metals such as gold, silver, platinum and palladium is contemplated.
- When the system treated in the foregoing methods is biological, the monoclonal antibody or fragment thereof may be combined with a pharmaceutically acceptable carrier. Preferably, the monoclonal antibody or fragment thereof will not of itself cause an undesirable immune response of the biological system. The biological systems contemplated according to the invention include unicellular organisms, multicellular simple organisms, cellular component systems, tissue cultures, plants and animals, including mammals.
- The present invention also contemplates methods for removing heavy metallic cations, such as lead, or radioactive compounds from human fluids such as blood, serum or lymph by utilization of immobilized monoclonal antibodies or fragments thereof. An extracorporeal shunt placed in the patient permits removal of the body fluid and its reintroduction. Passing the body fluid extracorporeally through a bed of immobilized monoclonal antibody or fragment thereof accomplishes the desired removal. An especially preferred method is use of an extracorporeal shunt for blood in combination with a monoclonal antibody or fragment tagged with a substance that is immobilizable. Such substances include substances for enzymes, e.g., sulfanilamide and carbonic anhydrase, ligands and proteins, e.g., avidin and biotin, and magnetic compounds, e.g., organic iron derivatives that will be attracted to an electromagnetic source. The monoclonal antibody (or fragment) tagged

with immobilizable substance is injected into the patient through the shunt. After circulation and complexation with the small moiety in vivo, the shunt is vented and the complex carrying the immobilizable 5 substance is removed extracorporeally from the shunted blood by the appropriate immobilization technique such as affinity binding or magnetic separation.

When a method for adding a monoclonal antibody (or fragment)-small moiety conjugate to a biological or 10 inanimate system is contemplated, the monoclonal antibody or fragment will preferably be bifunctional. The second binding site of the monoclonal antibody or fragment will be reactive with a selected component of the system. That component may be a complex organic 15 molecule, living cells, selected tissue of a tissue culture or a selected tissue of an animal. In this method, the small moiety will exert a desirable action upon the component of the biological or inanimate system targeted.

20 The present invention also contemplates a kit for assaying the presence and quantity of small moiety in a biological or inanimate system. The kit includes aliquots of monoclonal antibodies or fragments thereof in the appropriate buffer, as well as a fixed support 25 with antigen probe for absorption of the small moiety, washing solutions, reagents such as enzyme substrates, and antisera conjugated to a detectable substrate which antisera are generally reactive with all antibodies produced by the source from which the monoclonal 30 antibodies or fragments thereof are derived.

This invention is directed to the use of the genes for the antibodies or for coding for any portion of the antibody molecule or derivatives thereof.

Synthetic genes created for the purpose of coding for 35 the antibodies or any portion thereof are included. The invention also includes the expression of these genes in any bacteria, yeast, plant, animal, virus, fungi, or any

other organisms for any purpos . Such purposes include treatment of toxic waste soil, water or effluent; mining of metals using these organisms; bioremediation; medical uses; and agricultural uses.

5 The invention is further directed to a cocktail of the monoclonal antibodies or fragments thereof which immunoreacts with a group of different small moieties. This cocktail can be used to remove, for example, heavy metal and small organic molecule contaminants from a
10 medium or to remove a large mixture of heavy metals for which there is no cross-reactive singular monoclonal antibody.

The invention is also directed to a purified class of polyclonal antibodies having high specificity
15 for a group of small moieties with similar coordination chemistry and electron configuration. These polyclonals constitute the sensitized antibodies present in the body fluids of a mammal immunized with the immunogen compound according to the invention. Collection of the immunized
20 animal's fluid, e.g., blood, followed by affinity column purification using the immunogen compound as a probe will concentrate all the antibodies reactive toward the small moiety. Although this animal's immune cells can be used to form the hybridomas discussed above, at this
25 stage of the process, the animal will produce the polyclonals of the invention. Typical animals useful in this regard are goats, sheep, pigs and cows.

Brief Description of the Drawings

30 Figure 1 shows a graph of the results of an immunoassay. The results depict the competitive binding of mercuric ion and magnesium ion for a monoclonal antibody to mercury.

Figure 2 shows a graph of an immunoassay.
35 The results depict the competitive inhibitory binding of mercury and various divalent cations for a monoclonal antibody to mercury.

Figure 3 is a graph of the results of an immunosorbent assay of the binding of a monoclonal antibody to several heavy metal ions. The monoclonal antibody is specific for mercuric cations.

5

Detailed Description of the Invention

The monoclonal antibodies and related fragments of the present invention are key to the development of methods for detecting, adding, neutralizing or removing 10 minute quantities of small moieties. Until the present invention, it was not possible to produce antibodies to small moieties such as exposed metal cations per se or to small linear organic compounds, especially those without rings. The novel techniques for incorporating 15 small moieties into immunogen compounds and for administering these immunogen compounds to immune cell hosts allow production of the desired, immunospecific monoclonal antibodies according to the invention. These methods are believed to constitute an advancement in the 20 understanding of immunology.

Although not intended as a limitation of the invention, it is now believed that mammalian immunogenic reactivity can be elicited by small moieties. While they are smaller than the recognized epitopal size of 25 approximately 20-25 angstroms, the small moieties nevertheless can epitopally bind.

Notwithstanding these beliefs, the invention contemplates monoclonal antibodies (and fragments thereof) to small moieties, the hybridomas therefor, the 30 immunogen compounds for carrying the small moieties and inducing immunogenicity, and methods for detection, addition, neutralization or removal of small moieties using the monoclonal antibodies or fragments thereof.

Monoclonal Antibodies

35 The monoclonal antibodies of the invention are mammalian immunoglobulin proteins, preferably IgG, IgA, or IgE classes, which have strong affinity constants for

specific small moieties and/or classes thereof. They are characterized by selective immunoreactivity with a class of small moieties having similar coordination chemistry and electron configuration. Preferably, they

5 exhibit high specificity toward a particular, individual small moiety and a substantially lower immunoreactivity with other small moieties including those with similar electron configurations. The monoclonal antibodies have an association constant for the selected small moiety

10 that is at least about 100 fold and preferably at least about 10,000 fold greater than the association constant for the other small moieties. With respect to heavy metal cations, the especially preferred IgG class of monoclonal antibodies of the present invention exhibit

15 discriminatory dissociation constants of about 10^{-6} to about 10^{-12} . One example is a monoclonal antibody of the IgG class which is produced by hybridoma 4A10B4, ATCC number HB10381, and has a dissociation constant for mercury cation of less than about 10^{-9} but does not bind

20 cadmium, copper, zinc, lead, nickel and cobalt cations to any appreciable extent. Another example is a monoclonal antibody of the IgG class which is produced by hybridoma 3H7G5, ATCC number HB10382, and has a low dissociation constant for lead cation and also binds to

25 gold and mercury.

With respect to small organic molecules, the IgG, IgA and IgE classes of monoclonal antibodies of the present invention exhibit discriminatory dissociation constants of at least about 10^{-6} . Examples include

30 monoclonal antibodies that are selective for glutathione, serine ester, N-blocking groups for amino acids, trichloroethylene, polychlorinated biphenyl, ethyl mercaptan, chlordane and hydrophobic residues.

The monoclonal antibody fragments, single

35 chains, fragments of the chains and mimetic variable regions function like the monoclonal antibodies of the invention. They display an ability to complex with the

small moieties as described above. In the remaining discussion, it will be understood that mention of the monoclonal antibodies includes antibody fragments, single chain fragments as well as the mimetic variable regions.

Immunogen Compounds

The immunogen compounds for generation of the specific immunogenicity of the monoclonal antibodies are based upon the hapten-carrier concept. The present invention, however, broadens this concept so that the hapten is coordinated at the end of a spacer arm covalently bonded to the carrier. The spacer arm is adapted so as to be semi-rigid and to hold the small moiety in an exposed position relative to the carrier. This arrangement is also adapted to maintain the small moiety in a substantially exposed and preferably, essentially completely exposed state. These factors combine substantially to avoid chelating, encroaching or inclusion of the small moiety by the spacer arm and/or the carrier.

The spacer arm, as characterized above, may be an oligopeptide, an aliphatic compound, or an aliphatic fragment. In the latter two instances, the aliphatic compound or fragment may be covalently bonded to the carrier by means of a Schiff base reaction with an aldehyde group, an amide reaction with an amine or carboxylic acid group using a peptide activator such as carbodiimide, acid chloride and the like, an ester reaction with a hydroxyl or carboxylic acid group using a Schotten Bauman reaction, or azide or acid catalysis reaction, a sulfide reaction using a sulfide coupling agent, or other known coupling reactions for joining organic molecules to proteins. See for example Kabat, E.A., Structural Concepts In Immunology and Immunochemistry, 2nd Ed., Holt, Rinehart and Winston, New York, 1976 (a review text of such methods) and Jaime Eyzaguirre, Chemical Modification of Enzymes: Active

Site Studies, John Wiley & Sons (1982), the disclosures of which are incorporated herein by reference. The oligopeptide, aliphatic compound or fragment will contain backbone groups which provide semi-rigidity to

5 the spacer arm. Preferred groups for developing this semi-rigidity include peptide bonds, olefin bonds, olefinic conjugated systems, ester groups and enone groups. Optionally, and especially where immunogenicity of the small moiety appears difficult to generate, one

10 or more aromatic rings can be incorporated into the spacer arm to stimulate the development of an immune response.

In general, the oligopeptide spacer arm has the following formula:

15 - X - (R) - Y
wherein X is a coupling group that will bond to the carrier, R is one or more amino acid residues and Y is the Lewis Acid or Base group(s) for small moiety coordination.


20 In general, the aliphatic compound or fragment spacer arm has the following formula:

- X - (Q) - Z
wherein X is a coupling group that will bond to the carrier, Q is a semirigid aliphatic moiety containing
25 ester, amide, keto, olefin or aromatic groups and the like, and Z is a Lewis acid or Base group(s) for small moiety coordination or is a group that will form a covalent carbon bond with an organic small moiety to form a mimic.

30 Preferably, an oligopeptide or aliphatic compound is used as the spacer arm when the small moiety is a metallic cation. In this instance, the pendent Lewis base groups will preferably be positioned at the spacer arm end remote from the carrier. These Lewis
35 base groups function as the coordination site or sites for the metal cation. It is preferable that the deformability of the electron shells of the Lewis base

groups and the metal cations be approximately similar. Accordingly, sulfur groups can serve as the Lewis base groups when the metal cations are transition metals or inner transition elements. Nitrogen containing groups 5 are preferably employed as the Lewis base groups when aluminum, lithium, boron, strontium, magnesium, and other small atomic diameter metallic cations function as the small moieties.

When the small moiety is a small organic 10 molecule, the spacer arm will be covalently bonded or bondable to it. The resulting compound will be a spacer arm-small moiety mimic. The semi-rigidity of the spacer arm portion of the mimic holds the small moiety portion in a position exposed and remote from the carrier. 15 Preferred classes of spacer arm mimics for this aspect of the invention include aliphatic carboxylic acids, amines and aldehydes having semi-rigid backbones and having tails which duplicate the structure of the small moiety. For example, when the small moiety is 20 trichloroethylene, an appropriate spacer arm - mimic is N -(trichloroacryoyl) glycine. In general, the structure of the spacer arm-mimic is as follows:



wherein X and Q are defined as given above, A is a bond 25 or group attaching M₁ to Q and M₁ represents the organic molecule which is acting as the small moiety. An example of this technique as applied to organic molecules is use of glutathione. As discussed in detail below, monoclonal antibodies specific to glutathione 30 have been made.

The spacer arm mimic can as well act as a tagged small moiety. It participates in the methods for detection that employ immobilized monoclonal antibody. Spectrally active groups can be joined to the spacer arm 35 mimic or incorporated therein to provide a discernable, detectable signal. Such groups include fluorescent

groups, colorimetric groups, U.V. groups and others known in the art.

The carrier of the immunogen compound is a large biopolymer that is known to participate in the development of hapten antigenicity. Blood serum proteins, amylopectins, polysaccharides, fetal serum components, biologically acceptable natural and synthetic proteins and polyamides such as polyglycine can serve as the carriers. Preferred carriers include serum and tissue proteins. Examples are keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA). Other examples include ovalbumin and chicken gamma globulin. These carriers have sites for coordinate bonding of the spacer arm. Such sites are preferably populated by amine groups, carboxylic acid groups, aldehyde groups and/or alcohol groups.

Production of Hybridomas

The production of hybridomas according to the invention generally follows the Kohler, Milstein technique. Many of the small moieties, however, toxify the mammalian system being used as a source of immune cells. This effect makes it important to determine the highest allowable dose of small moiety and/or immunogen compound that can be used over a substantially long period of time without killing the host.

Pursuant to the Kohler, Milstein technique, immunization of the mammalian host is accomplished within this dose parameter by subcutaneous or intraperitoneal injection of the immunogen compound in adjuvant. Administration is repeated periodically and preferably for at least four injections. Three days before the spleen is removed, a priming injection of immunogen compound is again administered.

At this stage of the procedure, the immunized mammal also secretes into its blood stream polyclonal antibody to the small moiety. Isolation and concentration of the polyclonal by known affinity

binding techniques produces the polyclonal composition of the invention. Goats, pigs, rabbits, cows, horses, sheep and the like are useful as mammalian sources for the polyclonal and hybridoma productions.

5 After their separation, the spleen cells are fused with immortal mammal cells such as mouse myeloma cells using the techniques outlined by Kohler and Milstein. Polyethylene glycol (PEG) or electrical stimulation will initiate the fusions.

10 The fused cells are then cultured in cell wells according to culture techniques known in the art. Cellular secretions in the culture medium are tested after an appropriate time for the presence of the desired cellular products.

15 Selection Technique

The selection technique for identifying the appropriate monoclonal antibody is an important aspect for determining the immunospecificity desired according to the invention. The selection techniques according to 20 the invention call for determining the binding affinity of the hybridoma cellular products against the small moiety and against cross-reactive controls. In particular, hybridoma culture fluid is tested in screening assays against the small moiety, the carrier, 25 the carrier-spacer arm product and the immunogen compound as well as optionally against the spacer arm-small moiety coordinate. In instances where the small moiety is an organic compound, cross-reactivity controls against a spacer arm-mimic wherein the mimic tail 30 includes the backbone of the small moiety but not the carbon substituents of the small moiety, may be included. This will eliminate cross-reactivity with the carbon backbone of the spacer arm-mimic.

Screening assays can be performed by 35 immunoenzymatic-assay, immunofluorescence, fluorescence-activated cell sorter, radioimmunoassay,

immunoprecipitative assay or inhibition of biological activity.

The hybridoma cultures selected will exhibit strong binding characteristics to the small moiety (and 5 immunogen compound) and exclude binding with the spacer arm-carrier product and with the carrier itself.

Following the identification of cell cultures producing the desired monoclonal antibodies, subcloning to refine the selected culture can be performed. These 10 techniques are known to those skilled in the art. See for example James Goding, Monoclonal Antibodies: Principles and Practice, 2nd Edition, Academic Press, San Diego, CA 1986, the disclosure of which is incorporated herein by reference.

15 Briefly, the appropriately selected cell culture is separated into one cell units which are then recultured. The subclone cultures are then again tested for specific immunoreactivity, lack of cross-reactivity and the amount of monoclonal antibody secreted. Those 20 subcultures exhibiting the highest amounts of secreted monoclonal antibody are chosen for subsequent pilot development.

Following the foregoing techniques, hybridomas producing monoclonal antibodies to mercury cation and to 25 the group of lead, gold and mercury cations have been developed. These perpetual cell lines, designated 4A10 and 3H7 respectively are maintained in culture medium and in frozen medium at liquid nitrogen temperature at the laboratories of BioNebraska.

30 The immunogenic host for these hybridomas was the BALB/c mouse and the fusion partner was the mouse myeloma cell line P3X63-Ag8.653. Immunizations were accomplished with the immunogen compound formed from KLH, glutathione and the metallic cation functioning as 35 the small moiety in complete Freund's adjuvant.

Deposits of these hybridomas with the American Type Culture Collection (ATCC) depository were made on

March 13, 1990 by the applicants. The respective ATCC deposit numbers for the foregoing BioNebraska cell lines respectively are 4A10B4, ATCC number HB10381 and 3H7G5, ATCC number HB10382. Applicants accept and will

- 5 designate the provisions of the Budapest Treaty for these deposits. Applicants agree that the hybridomas will be available upon publication or issuance of this patent application. Applicants agree that upon request the Commissioner of Patents shall be entitled to direct
- 10 submission of the hybridomas to a depository or other recipient he shall designate. Applicants certify that the hybridomas are viable. Applicants certify that the hybridomas are also available from BioNebraska, Inc. pursuant to and under the provisions of the Budapest
- 15 Treaty for microorganism deposits. Applicants agree that the foregoing conditions apply also to their own maintenance of the hybridoma cultures. Applicants assure that they will maintain their hybridoma cultures for at least thirty years and will request the same of
- 20 the international depository.

Fragments and Recombinant Method

- Fragments of the monoclonal antibodies, such as the F_{ab} and $F_{(ab)'}^{'}$ fragments can be generated by well-known techniques. For example, cleavage of the
- 25 monoclonal antibody with papain enzyme will produce the $F_{(ab)'}^{'}$ fragment while cleavage with papaverine will produce the F_{ab} fragment. See "Antibodies. A Laboratory Manual," E. Harlow and D. Lane, Cold Spring Harbor Laboratory, 1988.

- 30 A recombinant method for generating the fragments of monoclonal antibodies as well as the monoclonal antibodies themselves utilizes the techniques for generating plasmid libraries containing antibody repertoires such as the techniques developed by Lerner et al., Science, 246, p.1275 (1989) and Winter et al., Nature, 341, 544 (1989). According to these methods, a library of sensitized immune cells is produced by
- 35

immunizing the mammal with immunogen compound. Restriction and isolation of the set of antibody genes from the library of immune cells of the mammal forms the set of genes for creation of the gene library. This set of genes can be used without further manipulation or can be further restricted to yield gene fragments for the F_{ab} , $F(ab)'$, single chain, single chain fragments and mimetic variable regions. The library of antibody genes is spliced into an appropriate vector and the recombinant vector inserted into a compatible host such as E. coli. The recombinant host cells produce a library of monoclonal antibodies or fragments thereof pursuant to the expression code provided by the recombinant vector. By application of the Winter and Lerner techniques to the recombinant method of the present invention the library of gene fragments for the F_{ab} , $F(ab)'$, single chain, single chain fragment, or mimetic variable region segments are produced in vivo. These methods permit production of the appropriate monoclonal antibody library as well.

Following preparation of the repertoire of recombinant cells, the cellular library is cloned and the individual clones screened for the monoclonal antibody or fragment thereof that selectively reacts with small moiety. Pursuant to the Lerner and Winter techniques, any of the known methods for screening recombinant DNA libraries such as radioassay of colony transfers. The initial screen employs the immunogen compound or a combination of the antigen probe and the small moiety as a screening reagent. Cross-reactivity with the carrier and spacer arm is eliminated by selection of those monoclonal antibodies or fragments from the first pass that do not react in a second and third assay with the carrier arm or carrier spacer arm moieties alone.

Through these techniques, the need to perform cellular fusions and grow hybridomas is eliminated. The

techniques streamlin the small moiety monoclonal antibody production and av id tedious hybridoma formation.

Methods of Application

- 5 According to the invention, the monoclonal antibodies can be used to advantage for detection, neutralization, addition or removal of small moieties from biological or inanimate systems. These methods apply to qualitative and quantitative analyses or
- 10 detection of such embodiments as minute concentrations of toxic metal cations, desirable metal cations such as gold, silver, platinum and the like, herbicides, pesticides and toxic small organic molecules in aqueous liquid systems and minute quantities of organic and
- 15 inorganic molecules in there biological or environmental systems or in such compositions as perfumes, cosmetics, pharmaceuticals, health care products, skin treatment products, pesticides, herbicides, toxic solvents used in the production of semi-conductor and integrated circuit
- 20 components and production materials for electronic components. In each application, the presence of minute quantities of metallic cations or small organic materials could constitute deleterious contaminants.
- 25 Their ready and early detection will avoid later production or regulatory set-backs.

Alternatively, the presence of minute quantities of small moieties in certain instances may be desirable. For example, the presence of small organic molecules in food products, cosmetics and perfume and

30 the presence of inorganic moieties in such mixtures as doping materials for semi-conductors and integrated circuits contributes to the properties of the product.

Quality control of the presence and concentration of these small moieties is essential for the functioning of

35 the product. The detection methods of the invention enable ready and early measurement of the presence of

such moieties and avoid later production or regulatory difficulties.

In the broadest aspect, the method for detection utilizes the complexation reaction of the 5 monoclonal antibody or fragment thereof and the small moiety or group thereof and an assay technique for the presence of the complex. The complex may be immobilized before or after its formation or may be treated in similar fashion to isolate it from the uncomplexed 10 reagents and antibody. Assays such as ELISA, radioimmunoassay, sandwich, antisera antibody reaction, enzyme coloration reaction and tagging can be used for quantification.

The small moieties in biological or inanimate 15 systems can also be removed by methods according to the invention, especially those small moieties constituting the embodiments mentioned above. In the main, mixture of the monoclonal antibodies or fragment thereof with the biological or inanimate system followed by treatment 20 with an immobilized or immobilizable substance that is capable of binding or reacting with the antibodies, fragments and/or complexes will remove the small moieties.

The immobilization of the monoclonal antibodies 25 or fragments thereof can also effect removal. Such immobilization can be accomplished by techniques known to those of skill in the art. See, for example, Affinity Chromatography, C.R. Howe & P.D.G. Dean, John Wiley & Sons, London 1974, the disclosure of which is 30 incorporated herein by reference. Removal is accomplished by passing the system suspected as having the small moieties over the immobilized monoclonal antibodies designed to be specific for the small moiety or group of small moieties sought to be removed.

35 A further application of this removal method involves the use of a magnetic, affinity or photolytic agent bound to or bindable a non-active portion of the

monoclonal antibody or fragment thereof. The agent permits removal of the complex of antibody (or fragment) through binding, coordination reaction or other physiochemical process designed to separate and/or 5 immobilize the complex. Examples include affinity binding, e.g., with avidin and biotin or carbonic anhydrase and sulfanilamide or photolytic binding, e.g., with azide photoreaction with an amine group containing column, and with an iron containing agent that will 10 separate magnetic attraction to a magnetic source.

An advantage of this method is the removal of undesirable small moieties in the presence of similarly structured desirable chemical compounds. For example, whole blood from a patient suffering from lead poisoning 15 can be removed from the patient, optionally filtered to return the cellular blood components to the patient, and the serum or blood passed over immobilized monoclonal antibodies specific for the lead. Alternatively, the soluble monoclonal antibody or fragment can be tagged 20 with a magnetic agent that will allow separation of the complex from extracorporeal blood by magnetic attraction means after the antibody has been circulated through the patient. The purified serum or blood can then be returned to the patient. The lead will be removed but 25 other blood serum components such as zinc, calcium, iron and the like will not.

Likewise, a doping mixture for integrated circuits which contains a trace transition metal can be passed over immobilized monoclonal antibodies which are 30 specific for an undesirable neighboring transition metal. The complexation will remove undesirable trace amounts of similar transition metals and produce an ultrapure doping mixture for the integrated circuit components.

35 In the same vein, precious metals such as gold, platinum and silver can be removed from sources such as sea water. The source is passed over immobilized

monoclonal antibodies or fragments thereof which are specific for the precious metal.

- Additionally, the recombinant methods discussed above provide a means for sustained reproduction of the
- 5 monoclonal antibody or fragment thereof within systems where the small moiety is to be removed or otherwise treated. The recombinant cells, for example, algae, E. coli, fungi, or iron bacteria, are cloned with the appropriate genetic machinery for expression of the
- 10 monoclonal antibody or fragment thereof, as for example, an intracellular constituent within the cytoplasm. The cells have an ability to absorb the small moiety, especially heavy metals, so that the small moiety becomes bound to the monoclonal antibody or fragment
- 15 thereof within the cytoplasm. Inoculation of the recombinant cells of the system into containing the small moiety, culturation of the recombinant cells within the system and harvest of the nature culture produces removal and/or treatment of the small moiety.
- 20 A typical system would be a water pond containing mercury or gold ions. Inoculation, culturation and harvest of recombinant algae with respect to the pond would isolate and remove the mercury or gold.

Methods for adding small moieties to biological

25 or inanimate systems focus on the delivery of the small moiety to a particular site. In this instance, the monoclonal antibodies will be bifunctional. The second binding site will be adapted to complex with a selected site within the biological or inanimate system. In this

30 fashion, the monoclonal antibody-small moiety conjugate will deliver the small moiety to a specific site.

This method is particularly suited for heterogenous delivery processes. These processes enable the non-uniform concentration of the small moiety in a

35 system that would otherwise cause its uniform or homogenous distribution. Examples include the delivery of anti-cancer compounds to target organs and tissues

within a mammalian system, the delivery of radioactive compounds to specific organs and/or tissues in biological or inanimate systems and the delivery of metallic cations or small organic molecules to specific sites within a system. Fluid or semi-fluid flow of system ingredients would be preferred so that transport of the monoclonal antibody-small moiety conjugate can be rapidly made. The presence of a fluid medium, however, is not an important characteristic. Gels, semi-solidified systems and the like can be employed as long as some semi-fluid connection is present for diffusion of antigen and antibody.

When and immobilization and/or coordination of the small moiety is a step called for by the methods of detection, removal, addition or removal, the step can be accomplished through an antigen probe. The antigen probe generally binds or reacts with the small moiety and has the formula indicated above. Typically it is bifunctional so that after binding or reacting it will also immobilize, separate or otherwise distinguish the small moiety.

For administration of the monoclonal antibodies to biological systems, the antigenicity of the monoclonal antibodies themselves will preferably be minimized. Use of species-specific cell sources for generation of the hybridomas is an appropriate technique for minimizing the antigenicity of the monoclonal antibodies. Cross-reaction studies of the host and the monoclonal antibody can also be made to determine lack or minimization of monoclonal antibody sensitivity. A preferred means for avoiding adverse immune reaction is the use of the Fab or F(ab)₂ fragments of the monoclonal antibodies of this invention. These fragments do not contain the heavy chain tail primarily responsible for such immune reactions and are made by known methods.

In instances involving in vivo application, the dosage level and routes of monoclonal antibody

administration will follow the judgment of the medical practitioner who is in an appropriate position to understand the needs and problems of the patient or mammal. In these situations, the dosage levels of 5 monoclonal antibody compositions being administered will be consonant with the toxicity and sensitivity levels determined for the patient or mammal. The monoclonal antibody compositions will generally be combined for administration with a pharmaceutically acceptable medium 10 such as water, alcohol, buffered aqueous medium, excipients, diluents and the like. Active transport agents can also be included. In general, the processes of administration for removal or addition of small moieties will maintain concentrations as high as 15 possible so that the period for patient intervention is minimized. In each instance, consideration of the physiological characteristics of the small moiety will be important for determining the dosage levels and route of administration.

20 Specific Applications

A particular application of the present invention contemplates a method for the production of monoclonal antibodies specific for the mercuric cation or another toxic, heavy metal cation. In accordance 25 with this method, the heavy metal cation in question is combined into an immunogen compound as described above and suspended in an aqueous medium. The preferred protein carrier for the immunogen compound in this instance is keyhole limpet hemocyanin. The preferred 30 spacer arm in this instance is an oligopeptide which has sulfhydryl groups capable of coordinating with the heavy metal cation. Glutathione is especially preferred as the spacer arm. The suspension of immunogen compound is used to immunize a host mammal such as a mouse following 35 the techniques outlined above. The laboratory strain of mouse designated BALB/c is particularly preferred.

Cells of the immunized host's spleen are collected and converted into a suspension. These spleen cells are fused with immortal cells as described above. Preferably, myeloma cells of the same animal species as 5 the immunized host are used as the fusion partner. Typically, a cell fusion promoter such as polyethylene glycol is employed to cause formation of the hybridoma cells. The hybridoma cells are diluted and cultured in a medium which does not allow for the growth of unfused 10 cells.

The monoclonal antibodies produced and secreted by the hybridomas are thereafter assayed for the ability to bind immunologically with the heavy metal cations used for immunization. They are further selected for 15 lack of cross-reactivity with carrier and with carrier-spacer arm.

The preferred assay method in this context is an enzyme-linked immunosorbent assay.

The resulting monoclonal antibodies are 20 specific for toxic heavy metal cations and exhibit strong complexation to the heavy metal cations when in the presence of spacer arm, the spacer arm-carrier composition and other similarly structured cations. Preferred monoclonal antibodies are selectively 25 immunoreactive with cations of mercury, lead, cadmium, strontium, nickel, cobalt, gold or arsenic.

According to an embodiment of a method for detecting the presence of heavy metal cations, an immobilized antigen probe such as a coordinating 30 compound is combined with the unknown mixture containing the toxic metal cation. The heavy metal cation complexes with coordinating compound and is immobilized thereto. Optional removal of the non-immobilized components leaves a mixture of the immobilized heavy 35 metal cation. Addition of the monoclonal antibody specific for the heavy metal cation forms an immobilized cation-monoclonal antibody complex. Its presence and

- concentration can be assayed by an ELISA technique, antisera antibody-enzyme linked assay or other tagging or visualization technique known to those of skill in the art. An alternative sequence utilizes formation of 5 the cation-monoclonal antibody in solution first followed by its immobilization with an immobilized antigen probe such as glutathione. In both alternatives, the non-immobilized monoclonal antibody typically is removed before the assay is conducted.
- 10 A kit for quantitatively measuring the presence of a heavy metal cation by the method described above is a further aspect of the invention. The kit will include the immobilized coordination compound, preferably, attached to a solid support such as the well of a
- 15 microtiter plate or a chromatographic material, and a portion of monoclonal antibody specific for the heavy metal cation or group of metal cations in question, wherein the portion is preferably metered into several aliquots of varying, known concentration. A third
- 20 component of the kit will be the visualization or tagging assay material for determination of the presence of the monoclonal antibody-metal cation complex. If desired, a meter or other device for detecting and signaling the level of visual or other reading from the
- 25 assay may also be included.

The invention will be further characterized by the following examples. These examples are not meant to limit the scope of the invention which has been fully set forth in the foregoing description. Variation 30 within the concepts of the invention are apparent to those skilled in the art.

Example 1
Mercury Cation Monoclonal Antibodies

35 A. General Procedures

1. Generation of Hybridomas

Hybridoma antibodies have been produced with the spleen cells of BALB/c mouse that had received

multiple injections of mercuric ions reacted with glutathione to produce a mercuric ion coordinated covalent compound, which was covalently bound to keyhole limpet hemocyanin ("KLH"). The KLH incomplete Freund's 5 adjuvant was utilized to assist in the elicitation of an immune response in the host animal. Glutathione is a three amino acid residue peptide having one reactive sulphydryl group which forms a coordinate bond with mercuric ions.

10 Of 134 hybridomas isolated, four were determined to be producing monoclonal antibody specific for glutathione as set forth below in Table 1. In addition, three other hybridomas (1F10, 4A10, and 3E8) were producing monoclonal antibodies that were strongly 15 positive against glutathione-mercuric ions but negative against glutathione without mercuric ions (Table 1.). These three antibodies were subcloned by limiting dilution for further characterization. A fourth antibody (3F5), not included in Table 1, which appeared 20 to be specific for glutathione but bound more tightly in the presence of mercuric ions, was also subcloned.

25 TABLE I: ELISA Results From Initial Screening of Hybridoma Antibodies Reactive With Glutathione or Glutathione-Mercuric ions

<u>Hybridoma</u>	<u>Glutathione</u>	<u>Glutathione-mercuric ions</u>
1H11	1.202	1.246
2A9	1.052	0.758
30 3A12	2.127	1.792
3H9	2.134	1.606
1F10	0.406	1.175
3E8	0.410	1.076
4A10	0.400	1.104
35 Negative ^b	0.456	0.428

*Values are the absorbance at 405 nm shown by the specified hybridoma antibody in the ELISA.

40 ^bThe value shown is the average absorbance at 405 nm of six wells on an ELISA plate that received culture

fluid containing a monoclonal hybridoma antibody specific for dinitrophenol instead of culture fluid containing a mercuric ion specific monoclonal antibody in the first step of the assay.

5

Only one positive subclone was obtained from hybridoma 3E8, and it subsequently lost its antibody-secreting ability. Several subclones secreting antibodies that were specific for mercuric ion were isolated from the other mercuric ion-specific hybridomas. The results of the analysis of these subclones and those from 3F5 with BSA-glutathione--mercuric ion and BSA-glutathione are shown in Table 2. All of the frozen hybridoma samples have been thawed from liquid nitrogen and assayed for persistence of antibody secretion after thawing.

20 TABLE 2: ELISA Results from Hybridoma Subclones Specific for Glutathione or Glutathione-Mercuric ions

	<u>Hybridoma</u>	<u>Glutathione</u>	<u>Glutathione-mercuric ion</u>
25	1F10.A6	0.289	1.048
	1F10.A9	0.300	0.979
	1F10.A11	0.285	1.015
	1F10.B1	0.302	0.861
	1F10.B2	0.271	0.952
	1F10.E2	0.292	1.005
30	4A10.B4	0.322	1.279
	3F5.A8	0.494	0.773
	3F5.B11	0.563	0.865
	3F5.D5	0.658	0.884
	Negative ^b	0.332	0.295

35

*Values are the averages of the absorbance at 405 nm of triplicate samples for each hybridoma subclone in an ELISA.

40

^bThe value shown is the average absorbance at 405 nm for six wells in an ELISA plate that received culture fluid containing a monoclonal hybridoma antibody specific for dinitrophenol instead of culture fluid

containing a mercuric ion-specific monoclonal antibody in the first step of the assay.

5

Based on this ELISA assay work, hybridomas 1F10 and 4A10 were further evaluated to determine if the antibodies secreted were specific for mercuric ions.

10

2. Determination of Mercuric-ion Specific Monoclonal Antibodies

Various methods were used to confirm that the antibodies secreted by hybridomas 4A10 and 1F10 were specific to mercuric ions. If the antibody being secreted by these hybridomas were specific, it should be possible to inhibit binding of the antibody to glutathione-mercuric ions by incubation in the presence of various concentrations of mercuric chloride. This competitive inhibition assay was conducted with antibody-containing culture fluids from the parental hybridomas 4A10 and 1F10. The results for inhibition of 1F10 by mercuric chloride and magnesium chloride are shown in Figure 1.

Figure 1 shows inhibition of binding of antibody secreted by hybridoma designated as 1F10 to immobilized glutathione-mercuric ion by various concentrations of magnesium ions. Metal ions at the indicated concentrations were incubated with culture fluid from the monoclonal antibody in an enzyme-linked immunosorbent assay ("ELISA") plate. The absorbance at 405 nm was determined for each sample, and the percent inhibition of each metal ion concentration was determined by the following formula (X100%):

35

Percent inhibition is determined by:

$$\frac{A_{405} \text{ of inhibitor} - A_{405} \text{ of neg. control}}{A_{405} \text{ of pos. control} - A_{405} \text{ of neg. control}}$$

Magnesium chl ride at the same concentrations as mercuric chloride was included as a control to rule out the possibility that inhibition could be due to excess amounts of divalent cations or increased ionic 5 strength of the incubation solution. It can be seen that 50% inhibition with mercuric chloride occurs between 0.0001 and 0.00001 M, while magnesium chloride approaches 50% inhibition only at the highest concentration.

10 Therefore, in both enzyme-linked immunosorbent assay (ELISA) and the competitive assay, the monoclonal antibodies were specific for mercuric ions. The preformation of a mercuric ion coordinate covalent complex is not a requirement for monoclonal antibody 15 recognition of mercuric ion. Thus, the monoclonal antibody reacts with free mercuric ions which are independent of coordinating agents.

Various other metals were assayed for inhibition of binding of the monoclonal antibodies to 20 mercuric ion. The cationic metals assayed include the ions of zinc, copper, cadmium, nickel, and arsenic. The results of these inhibition assays are shown in Figure 2. To produce these results the binding of monoclonal antibody secreted by the hybridoma designated as 1F10 to 25 immobilized glutathione-mercuric ions by various concentrations of divalent cations was examined. Metal ions at the indicated concentrations were incubated with culture fluid from the antibody in an ELISA plate. The absorbance at 405 nm was determined for each sample, and 30 the percent inhibition of each metal ion concentration was determined by the same formula used for Figure 1.

However, none of the metals showed a titratable inhibition of monoclonal antibody binding similar to that seen with free mercuric ions. Therefore, based 35 upon th heavy metal ions tested, th monoclonal antibodies produced by immunization with mercuric ions are specific for mercuric ions.

Further analysis shows that the monoclonal antibodies produced are specific for the mercuric ions per se and that glutathione is not needed for the monoclonal antibodies to react with and bind to the 5 mercuric ions. The monoclonal antibody from hybridoma 1F10 was assayed against BSA-glutathione, BSA-glutathione mercuric ions, and BSA-mercuric ions. When compared against a negative control consisting of a 10 monoclonal antibody specific for an unrelated antigen the results show that the monoclonal antibody binds to mercuric ion in the absence of glutathione.

15 BSA-glutathione adsorbed to the wells of a microliter plate effectively binds mercuric ions from solution and enables detection of mercuric ions in a concentration as low as 10^{-9} M (0.2 ppb) by the antibody (Table 3) without appreciable loss of sensitivity.

20 TABLE 3: Assay Utilizing BSA-Glutathione
Added to Polyvinyl Chloride Microtiter Plates

	<u>Hg Conc. (M)^a</u>	<u>A405</u>
	10^{-1b}	0.442
	10^{-2}	1.213
25	10^{-3}	1.453
	10^{-4}	0.936
	10^{-5}	1.364
	10^{-6}	0.962
	10^{-7}	1.113
30	10^{-8}	1.113
	10^{-9}	1.107
	0	0.394

35 ^aMercuric ion concentration refers to the concentration of mercuric chloride in the PBS added to the well to which BSA-glutathione had been absorbed.

40 ^bThe absorbance at concentrations of 10^{-1} M is only slightly higher than the control because the large numbers of ions present creates a substantial amount of stearic hindrance which prevents binding and is not evidence of any lack of specificity of the monoclonal antibody.

The specificity of the antibody reactivity for mercuric ion is shown in Figure 3. Here the reactions 5 of various coordinated heavy metal ions with the monoclonal antibody secreted by the hybridoma designated 10 indicate that it is specific for mercuric ions.

Phosphate-buffered saline ("PBS") containing metal ions at the indicated concentrations was added to 10 triplicate microtiter wells to which BSA-glutathione had been absorbed. After incubation at room temperature for 30 minutes, the plates were washed to remove unbound metals, and the plates were used for the standard ELISA to detect mercuric ions. In this experiment various 15 heavy metal ions at the indicated concentrations were added to microtiter plates to which BSA-glutathione had been adsorbed. The PBS containing the metal ions was allowed to incubate at room temperature for 30 minutes, and the plates were then used in an ELISA to determine 20 whether the monoclonal antibody would react with the bound metal. The data in Figure 3 show that mercuric ion is the only heavy metal ion which demonstrates a reasonable increase in absorbance.

25 B. Particular Preparations

1. Linkage of Mercuric Ions to Protein Carriers

To prepare antigen for injection and immunoassay, 136 mg HgCl₂ (400 umoles), 61 mg glutathione (200 umoles) and 54 mg NaCl were dissolved in 10 ml of 30 water. Thirty milliliters of cold ethanol were added and incubated for 30 minutes at 0°C. The reaction mixture was centrifuged at 10,000 g for 30 minutes, and the pellet was washed with 30 ml of cold ethanol. The pellet was dissolved in 200 ml of 40% dimethylformamide 35 pH 4.8, containing 200 mg of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide, and 1 g of either bovin serum albumin or keyhole limp t hemocyanin were added to the solution. The reaction mixture was stirred

at room temperature overnight. The mixture was then centrifuged as above, resuspended in PBS, and dialyzed overnight at 4°C against 4 liters of PBS.

5 2. Immunization of BALB/c Mice

BALB/c mice received multiple injections of the antigen prepared with 10 ug of protein per injection. The antigen was mercuric ion-glutathione-KLH emulsified in Freund's adjuvant. Complete adjuvant was used for 10 the first two injections, while incomplete adjuvant was used for all subsequent injections. After the fourth injection, a drop of blood from the tail of each mouse was collected separately in 0.5 ml of PBS, and each sample was assayed by ELISA for the presence of 15 antigen-specific antibody. The mice used for hybridoma production received an intraperitoneal injection consisting of 10 ug of antigen in PBS 3-4 days before cell fusion.

20 3. Hybridoma Production

The spleen was removed aseptically from a mouse, and the cells were isolated by placing the spleen in 5 ml of sterile PBS and teasing it with two sterile, 18-gauge hypodermic needles. The cell suspension was 25 added to an empty sterile, conical, 15-ml centrifuge tube and tissue fragments were allowed to settle for 1-2 minutes. The cells still in suspension were placed in a tube similar to that above and centrifuged at 300 g for 10 minutes at room temperature. The cells were then 30 washed 3 times by centrifugation in serum-free DMEM (Dulbecco's modified Eagle's medium). Spleen cells were co-pelleted with P3X63-Ag8.653 myeloma cells at a ratio of 4 spleen cells to 1 myeloma cell. The supernatant fluid was removed, and the pellet was suspended in 1 ml 35 of 35% polyethylene glycol for 1 minute. The polyethylene glycol was gradually diluted by addition of increasing amounts of serum-free DMEM over a period of

15 minutes. The cells were then suspended in HAT medium (Monoclonal Antibodies, Kennett, McKean, Backitt, eds. Plenum press 1981) at a concentration of 2×10^5 myeloma cells per ml, and 4 drops from a 5-ml pipet were added
5 to each well of 5 96-well microtiter plates. The plates were incubated in 10% CO₂ at 37°C for one week. At that time half of the culture fluid was withdrawn from each well and replaced by 2 drops of fresh HT medium (HAT medium without aminopterin), and the plates were
10 incubated as above for another week. Then, approximately 100 ul of culture fluid was taken from each well containing macroscopically visible cell growth, and the ELISA technique described infra was used
15 for identification of those culture fluids containing mercuric ion-specific antibodies.

4. Enzyme-Linked Immunosorbent Assay (ELISA)

Polyvinyl chloride microtiter assay plates were coated with antigen by addition of 50 ul of mercuric
20 ion-glutathione-BSA or glutathione-BSA at a concentration of 5 ug/ml in PBS to each well of the plate. The plates were allowed to incubate at room temperature overnight to allow the antigen to dry on the plate. Next day the plates were blocked by addition of
25 200 ul of 5% nonfat dry milk in PBS to each well; the addition of the dry milk blocked the remaining protein-binding sites. The plates were incubated for 2 hours at room temperature, then washed 3 times with ELISA wash (PBS with 0.1% of Nonidet P-40).
30 Fifty microliters of culture fluid being assayed for the presence of antigen-specific antibody were added to the appropriate well, and the plates were incubated at room temperature for 2 hours. The plates were again washed 3 times with ELISA wash, and 50 ul of
35 goat anti-mouse serum (Cooper Biomedical) diluted 1:1000 in 2% BSA in PBS were added to each well. After incubation and washing as above, 50 ul of rabbit

anti-goat serum conjugated to alkaline phosphatas (Sigma) diluted 1:1000 in 50 mM Tris-HCl, pH 8.0, containing 1 mM MgCl₂, 5% BSA and 0.04% NaN₃, were added to each well. After being incubated and washed as
5 above, 150 ul of phosphatase substrate (0.4 mM dinitrophenol phosphate in 1 M diethanolamine, pH 9.8, containing 25 mM MgCl₂) were added to each well.

10 The enzyme catalyzed conversion of dinitrophenol phosphate to dinitrophenol was allowed to proceed at room temperature for 30-60 minutes. The absorbance of each well at 405 nm (dinitrophenol) was measured with a UV spectrometer.

15 The use of other enzymes as sensors is also possible provided that such enzymes can be linked to an appropriate antibody, and catalyze a reaction which produces a color change. For example, beta galactosidase, urease, carbonic anhydrase or horseradish peroxidase could be utilized in this context.

20 5. Inhibition of Binding of Mercuric ion-Specific Antibody by Metals

25 Microtiter assay plates containing mercuric ion-glutathione-BSA were prepared as described above. After blocking the plates with non-fat dry milk, 25 ul of a solution containing a known concentration of the metal to be assayed were added to each of triplicate wells of the plate, along with 25 ul of culture fluid containing mercury-specific antibody. The concentrations of metal ranged from 2×10^{-1} M to 2×10^{-6} M, so the final concentration of metal in the wells ranged from 10^{-1} M to 10^{-6} M. The plates were incubated for 30 minutes at room temperature, washed with ELISA wash as above, and then assayed using the ELISA technique as described above. The absorbance at 405 nm
30 was measured for each well, and the percent inhibition of antibody binding for each concentration of metal was calculated according to the following formula (X100%):
35

Percent inhibition is determined by:

$$\frac{A_{405} \text{ of inhibitor} - A_{405} \text{ of neg. control}}{A_{405} \text{ of pos. control} - A_{405} \text{ of neg. control}}$$

5

The negative control measured the binding of a dinitrophenol specific antibody to the antigen mentioned above in the presence of the corresponding metal ions. The positive control consisted of triplicate wells that 10 contained 25 ul of mercuric ion-specific antibody and 25 ul of PBS with no metal.

6. Binding of Mercuric ions to
Immobilized Coordinating Spacer Arms

One hundred microliters of BSA-glutathione at a 15 concentration of 5 ug/ml were added to the wells of a microtiter plate and allowed to dry overnight. The plates were then blocked with nonfat dry milk as above. One hundred microliters of PBS containing a known concentration of the metal ion to be assayed were added 20 to triplicate wells on the plate, which was then incubated at room temperature for 30 minutes. After this incubation period the plates were washed with ELISA wash to remove unbound metal ions and then used in the standard ELISA to measure reactivity with the mercuric 25 ion-specific antibody.

7. Assay of Mercuric Ion-Specific Antibody Against
BSA Glutathione, BSA Glutathione-Mercury and
BSA-Mercury

Mercuric ion specific antibody secreted from 30 hybridoma 1F10 was assayed against BSA-glutathione, BSA-glutathione-mercury and BSA-mercuric ions. The results set forth below are the average absorbance plus the standard deviation of nine individual samples assayed against the three antigens.

35 Antigen	<u>1F10.All</u>	<u>Neg. Control</u>
BSA-glutathione	0.418 \pm 0.014	0.419 \pm 0.061
BSA-glutathione- mercuric ion	3.144 \pm 0.132	0.171 \pm 0.042
BSA-mercuric ion	2.861 \pm 0.092	0.223 \pm 0.027

Example 2
Lead Cation Monoclonal Antibodies

Pursuant to the procedures (part A) to generate hybridomas, and to make particular preparations (part B) given in Example 1, monoclonal antibodies to lead cation were produced. The following substitutions in those procedures and preparations were made:

- 10 A1) Generation of Hybridomas; lead cations instead of mercuric ion were used; 100 hybridomas were isolated; one showed specific lead cation reactivity.
- 15 A2) Determination of Specific Monoclonal Antibodies not conducted.
- 15 B1) Linkage; 400 umoles of lead chloride was substituted for the mercuric chloride.
- 20 B2) Immunization; The antigen was lead cation-glutathione-KLH.
- 20 B3) Hybridoma Production; The same procedure was used.

B4) Assay

Polyvinyl chloride microtiter assay plates were coated with antigen by addition of 50 ul of lead cation glutathione-BSA or glutathione-BSA at a concentration of 25 5 ug/ml in PBS to each well of the plate. The plates were allowed to incubate at room temperature overnight to allow the antigen to dry on the plate. Next day the plates were blocked by addition of 200 ul of 5% nonfat dry milk in PBS to each well; the addition of the dry 30 milk blocked the remaining protein-binding sites. The plates were incubated for 2 hours at room temperature, then washed 3 times with ELISA wash (PBS with 0.1% of Nonidet P-40).

Fifty microliters of culture fluid being assayed for the presence of antigen-specific antibody were added to the appropriate well, and the plates were incubated at room temperature for 2 hours. The plates were again washed 3 times with ELISA wash, and 50 ul of

goat anti-mouse serum (Cooper Biomedical) diluted 1:1000 in 2% BSA in PBS were added to each well. After incubation and washing as above, 50 ul of rabbit anti-goat serum conjugated to alkaline phosphatase (Sigma) diluted 1:1000 in 50 mM Tris-HCl, pH 8.0, containing 1 mM MgCl₂, 5% BSA and 0.04% NaN₃, were added to each well. After being incubated and washed as above, 150 ul of phosphatase substrate (0.4 mM dinitrophenol phosphate in 1 M diethanolamine, pH 9.8, containing 25 mM MgCl₂) were added to each well.

The enzyme catalyzed conversion of dinitrophenol phosphate to dinitrophenol was allowed to proceed at room temperature for 30-60 minutes. The absorbance of each well at 405 nm (dinitrophenol) was measured with a UV spectrometer.

The use of other enzymes as sensors is also possible provided that such enzymes can be linked to an appropriate antibody, and catalyze a reaction which produces a color change. For example, beta galactosidase urease, or horseradish peroxidase could be utilized in this context.

These measurements indicated that hybridoma 3H7, produced monoclonal antibodies that were strongly positive against glutathione-lead cation but were negative against glutathione alone.

Example 3
Experimental Procedure for Organic Small Moiety

30 1. Linkage of Trichloroethylene Mimic to Protein Carrier

To prepare antigen for injection and immunoassay, 136 (400 umoles) of N-(trichloroacryloyl)glycine and 54 mg NaCl can be dissolved in 200 ml of 40% dimethylformamide pH 4.8, containing 200 mg of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide, and 1 g of either bovine serum albumin or keyhole limpet hemocyanin. The reaction mixture can be stirred at room temperature overnight. The mixtur may

then be centrifuged resuspended in PBS, and can be dialyzed overnight at 4°C against 4 liters of PBS.

2. Immunization of BALB/c Mice

5 BALB/c mice can receive multiple injections of the foregoing antigen prepared with 10 ug of protein per injection. After the fourth injection, a drop of blood from the tail of each mouse can be collected separately in 0.5 ml of PBS, and each sample can be assayed by
10 ELISA for the presence of antigen-specific antibody. The mice to be used for hybridoma production can receive an intraperitoneal injection consisting of 10 ug of antigen in PBS 3-4 days before cell fusion.

15 3. Hybridoma Production

The spleen can be removed aseptically from a mouse, and the cells isolated as described above. Spleen cells can be co-pelleted with P3X63-Ag8.653 myeloma cells at a ratio of 4 spleen cells to 1 myeloma
20 cell. The supernatant fluid can be removed, and the pellet suspended in 1 ml of 35% polyethylene glycol for 1 minute. The polyethylene glycol can be gradually diluted by addition of increasing amounts of serum-free DMEM over a period of 15 minutes. The cells can be then
25 suspended in HAT medium (Monoclonal Antibodies, Kennett, McKean, Backitt, eds. Plenum Press 1981) at a concentration of 2×10^5 myeloma cells per ml, and 4 drops from a 5-ml pipet can be added to each well of 5 96-well microtiter plates. The plates can be incubated
30 as described above. Approximately 100 ul of culture fluid can be taken from each well containing macroscopically visible cell growth, and the ELISA technique described above can be used for identification of those desirable culture fluids.

4. Enzyme-Linked Immunosorbent Assay (ELISA)

Polyvinyl chloride microtiter assay plates can be coated with antigen by addition of 50 ul of N-(trichloroacryloyl)- glycine-BSA or glycine BSA at a concentration of 5 ug/ml in PBS to each well of the plate. The plates can be incubated and prepared for ELISA assay as described above.

Fifty microliters of culture fluid being assayed for the presence of antigen-specific antibody 10 can added to the appropriate well, and the plates can be incubated at room temperature for 2 hours. The plates can again be washed with ELISA wash, and 50 ul of goat anti-mouse serum (Cooper Biomedical) diluted 1:1000 in 2% BSA in PBS can be added to each well. After 15 incubation and washing as above, 50 ul of rabbit anti-goat serum conjugated to alkaline phosphatase (Sigma) diluted 1:1000 in 50 mM Tris-HCl, pH 8.0, containing 1 mM MgCl₂, and 0.04% NaN₃, can be added to each well. After being incubated and washed as above, 150 ul of 20 phosphatase substrate (0.4 mM dinitrophenol phosphate in 1 M diethanolamine, pH 9.8, containing 25 mM Mg₂ Cl) can be added to each well.

The enzyme-catalyzed conversion of dinitrophenol phosphate to dinitrophenol may be allowed 25 to proceed at room temperature for a sufficient time. Then, the absorbance of each well at 405 nm (dinitrophenol) can be measured with a spectrophotometer. Appropriate absorbance from the wells containing immunogen compound and lack of 30 absorbance from corresponding wells containing carrier will select the desired culture fluid and hybridoma.

Assay for Trichloroethylene in Water

Microtiter assay plates coated with a constant 35 amount of immobilized monoclonal antibody from the for going selected hybridoma can b prepared by the technique of L. Wide and J. Porath, Biochem. Biophys.

Act A, 130: 257-260 (1966). Briefly, this technique will involve addition of 50 μ l of metal-specific antibody (20 mg/ml in PBS) to each well of a microtiter plate. The plate will be incubated for 2 hrs., washed with PBS, 5 and blocked for 2 hrs. with 5% nonfat dry milk. The plates can then be saturated with radioactive trichloroethylene (^{14}C or ^3H). The plates can be incubated for a sufficient time, about 1 hour and then washed with the ELISA wash described above. Addition 10 of aliquots of water containing an unknown concentration of trichloroethylene can then be added to the assay plate wells. After incubating for a sufficient time, e.g. about 1, hour, the fluids from each of the wells can be removed and counted in a scintillation counter. 15 A comparison of the counts with a standard curve constructed from data produced by tests on known concentrations of trichloroethylene will yield the concentration of unknown in the test sample.

20

Example 4Procedure for N-blocking Groups for Amino Acids

Over 80% of the soluble proteins in biological cells including those of plants possess amino termini that are not free but chemically blocked. Determining 25 the identity of the blocked amino groups of proteins is extremely important in understanding the biological activities of the physiologically important protein molecules. However, only a handful of these blocked amino groups have been structurally determined because 30 the currently available HPLC-mass spectrometric method is difficult, tedious and extremely expensive. The present invention permits production of a set of monoclonal antibodies specifically designed to determine the terminal amines of proteins, both efficiently and 35 economically. Once such monoclonal antibodies are produced, these antibodies can be made commercially available as specialty reagent chemicals for the determination of protein structure. Pursuant to the

techniques described above two monoclonal antibodies have been produced that are specifically designed to detect N-acetyl group and/or N-acetyl amino acid, the acetyl group being most common amino-blocking group in 5 proteins.

Identification of the amino terminal group in phytochrome is an example of the difficulties mentioned above. It is blocked due to the posttranslational modification. However, conventional Edman degradation 10 does not reveal the chemical identity of the blocked amino terminal group in the protein and the amino acid sequencing deduced from cDNA codes is not useful, since the nature of posttranslational modifications are not determinable from the DNA base sequence. Identification 15 of the amino terminal groups in protein is tedious and requires a substantial amount of chromatographically purified N-terminal peptides, usually by ion exchange column chromatography or HPLC, for mass spectrometric analysis. Even in a mass spectrometric analysis, 50-100 20 nmol of purified peptide is required. In this respect, characterization of the blocked amino terminal groups in proteins is facilitated by the recent development of tandem mass spectrometry for relatively large peptides of 10 or more amino acid residues. In spite of this and 25 other developments, most of the blocked N-terminus groups in a number of proteins remains to be analyzed. The present invention contemplates a set of monoclonal antibodies specifically targeted for various N-blocking groups for terminal amino acids such as those listed in 30 the following table:

<u>Blocking Group</u>	<u>Occurrence(exampl.)</u>	<u>Reference</u>
N-acetyl	ovalbumin	Tsunasawa & Narita(1983)
5 Pyrrolidone carboxyl	immunoglobulins	Wold(1981)
Fatty acyl	E. coli murein lipoproteins	Wold(1981)
10 N-acetyl and O-phosphoryl (N-ser)	human lipocortin(I)	Bieman & Scoble(1987)
N-acetylglucosaminyl	N-terminal serine	Wold(1981)
15 O-phosphoryl	N-terminal serine	Wold(1981)
O-mannosyl	N-terminal serine	Wold(1981)
20 Pyruvate	N-terminal serine	Wold(1981)
α -ketobutyrate	N-terminal threonine	Wold(1981)
O-mannosyl	N-terminal threonine	Wold(1981)
25 O-adenosyl	N-terminal tyrosine	Wold(1981)

The first step in production of monoclonal antibodies to an N-block group on an amino acid is the attachment of this molecule (the hapten) to a larger carrier molecule. The haptens are N-acetyl blocked amino acids and the carrier molecule is keyhole limpet hemocyanin (KLH). This attachment has been accomplished to a degree of about 15 haptens per 100,000 kDa of protein.

35 The attachment was performed via a dicyclohexylcarbodiimide mediated synthesis of the N-hydroxysuccinimide activated ester of the amino acid. An undesirable side reaction involving polyester formation through reaction of the hydroxyl of the serine activated ester is avoided by using the N-acetyl serine activated ester immediately after synthesis and not concentrating the synthesis product.


40 The activated ester was then attached to KLH at pH 7.0 in aqueous solution. The attachment resulted 45 with about 60% blockage of exposed lysin residues as

determined by a TNBS assay. Pursuant to the immunization procedure discussed above, the N-acetyl serine conjugated KLH was injected and booster shots given. The resulting serum showed preferential binding

5 to N-acetyl serine conjugated BSA vs. unconjugated BSA. Pursuant to the hybridoma formation procedure discussed above, cell fusions were performed to obtain N-acetyl serine specific antibodies. Two monoclonals were isolated which reacted specifically to the haptens

10 conjugated BSA. The first antibody bound N-acetyl serine conjugated BSA more than 20 times stronger (by ELISA) than N-acetyl glycine conjugated BSA. (The N-acetyl glycine BSA synthesis was performed in the same manner as the N-acetyl serine BSA synthesis). The

15 second monoclonal showed only a slightly higher binding preference for N-acetyl serine BSA over N-acetyl glycine BSA (1.4 times greater reaction, ELISA determination).

International Application No: PCT/ /	
MICROORGANISMS	
Optional Sheet in connection with the microorganism referred to on page _____, line _____ of the description:	
A. IDENTIFICATION OF DEPOSIT:	
Further deposits are identified on an additional sheet <input checked="" type="checkbox"/> Murine hybridoma 4A10B4	
Name of depositary institution: AMERICAN TYPE CULTURE COLLECTION	
Address of depositary institution (including postal code and country): 12301 Park Drive Rockville, MD 20852 USA	
Date of deposit:	Accession Number:
March 13, 1990	HB 10381
B. ADDITIONAL INDICATIONS: (Leave blank if not applicable). This information is continued on a separate attached sheet <input type="checkbox"/>	
C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE: (If the indications are not for all designated States)	
D. SEPARATE FURNISHING OF INDICATIONS: (Leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later. (Specify the general nature of the indications e.g., "Accession Number of Deposit")	
<input checked="" type="checkbox"/> This sheet was received with the international application when filed (to be checked by the receiving Office)  (Authorized Officer)	
<input type="checkbox"/> The date of receipt (from the applicant) by the International Bureau is _____ WWS (Authorized Officer)	

International Application No: PCT/ /

MICROORGANISMS

Optional Sheet in connection with the microorganism referred to on page _____ line _____ of the description:

A. IDENTIFICATION OF DEPOSIT:Further deposits are identified on an additional sheet Murine hybridoma 3H7G5

Name of depository institution:

AMERICAN TYPE CULTURE COLLECTION

Address of depository institution (including postal code and country):

12301 Park Drive
Rockville, MD 20852 USA

Date of deposit:

March 13, 1990

Accession Number:

HB 10382

B. ADDITIONAL INDICATIONS: (Leave blank if not applicable). This information is continued on a separate attached sheet **C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE:** (If the indications are not for all designated States)**D. SEPARATE FURNISHING OF INDICATIONS:** (Leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later. (Specify the general nature of the indications e.g., "Accession Number of Deposit")

 This sheet was received with the international application when filed (to be checked by the receiving Office)

 (Authorized Officer)
 The date of receipt (from the applicant) by the International Bureau:

ws:

(Authorized Officer)

WE CLAIM:

1. A monoclonal antibody displaying immunoreactivity with a small moiety, which is produced by a
5 hybridoma of myeloma immortal cells and mammalian immune cells sensitized against an immunogen compound comprising a protein carrier, a spacer arm covalently bonded to the carrier and the small moiety coordinated in a substantially exposed state
10 with the spacer arm.
2. A monoclonal antibody according to claim 1 having high specificity for a particular small moiety and little cross-reactivity for other small moieties.
15
3. A monoclonal antibody according to claim 1 having high specificity for a group of small moieties with similar coordination chemistry and electron configuration and little cross-reactivity for other
20 small moieties.
4. A monoclonal antibody according to claim 2 wherein its dissociation constant for the particular small moiety is at least 10^2 smaller than its dissociation
25 constant for the other small moieties.
5. A monoclonal antibody according to claim 3 wherein the dissociation constant for the group of small moieties is at least 10^2 smaller than its
30 dissociation constant for the other small moieties.
6. A monoclonal antibody according to claim 1 wherein the spacer arm has at least one coordination site for the small moiety.

7. A monoclonal antibody according to claim 6 wherein the spacer arm coordination with the small moiety is monodentate.
- 5 8. A monoclonal antibody according to claim 2 which exhibits a substantially high degree of specific immunoreactivity toward the small moiety and is an immunoglobulin of the IgG, IgE or IgA class.
- 10 9. A monoclonal antibody according to any of claims 1 to 7 wherein the hybridoma is selected by the reactivity of its culture fluid toward the small moiety and its lack of reactivity toward the corresponding carrier-spacer arm compound that formed the immunogen compound.
- 15 10. A monoclonal antibody according to any of claims 1 through 7 wherein the small moiety is a metallic cation.
- 20 11. A monoclonal antibody according to claim 10 wherein the metallic cation is not a substantial physiological component of the mammal producing the mammalian immune cells.
- 25 12. A monoclonal antibody according to claim 10 wherein the metallic cation is derived from a metal selected from the group consisting of aluminum, lithium, boron, gallium, gallenium, arsenic, period 4 transition metals, and period 5, 6 and 7 metals, transition elements and inner transition elements.
- 30 13. A monoclonal antibody according to any of claims 1 to 7 wherein the small moiety is an organic compound having a molecular size of no more than about 15 atoms in length.
- 35

14. A monoclonal antibody according to claim 13 wherein the organic compound is a linear or branched aliphatic molecule or a small peptide.
- 5 15. A monoclonal antibody according to any of claims 1 to 7 wherein the carrier is KLH or BSA, the spacer arm is an oligopeptide with sulfhydryl groups and the small moiety is a cation of mercury, lead, cadmium, cobalt, arsenic, chromium, copper, nickel, 10 gold, strontium or zinc.
16. A monoclonal antibody according to claim 15 wherein the spacer arm is glutathione.
- 15 17. A monoclonal antibody according to any of claims 1 to 7 which also immunoreacts with the small moiety-spacer arm coordinate.
18. A monoclonal antibody according to any of claims 1 20 to 7 having an association constant for the small moiety that is at least about 10,000 fold greater than its association constant for the carrier-spacer arm compound.
- 25 19. A monoclonal antibody according to any of claims 1 to 7 wherein the hybridoma is formed from fusion of murine, human or caprine myeloma immortal cells and murine, lapin, equine, canine, feline, porcine, or primate immune cells from a mammal previously 30 immunized with the immunogen compound.
20. A monoclonal antibody according to claim 4 wherein the dissociation constant for the particular small moiety is at least about 10^{-6} .
- 35 21. A monoclonal antibody according to claim 15 wherein the small moiety is mercury and said hybridoma has

BioNebraska strain number 4A10B4 and ATCC deposit number ATCC HB10381.

22. A monoclonal antibody according to claim 15 wherein
5 the small moiety group is lead, mercury and gold and said hybridoma has BioNebraska strain number 3H7G5 and ATCC deposit number ATCC HB10382.
23. A hybridoma of myeloma immortal cells and mammalian
10 immune cells from a mammal previously immunized with an immunogen compound, wherein:
 - the immunogen compound is a protein carrier, a spacer arm covalently bonded to the carrier and a small moiety coordinated in a substantially exposed state with the spacer arm; and
 - 15 the hybridoma produces a monoclonal antibody which immunoreacts with the small moiety.
24. A hybridoma according to claim 23 wherein the
20 monoclonal antibody has a high specificity for a particular small moiety and little cross-reactivity for other small moieties.
25. A hybridoma according to claim 23 having high
25 specificity for a group of small moieties with similar coordination chemistry and electron configuration and little cross-reactivity for other small moieties.
- 30 26. A hybridoma according to claim 23 wherein the monoclonal antibody exhibits a substantially high degree of specific immunoreactivity toward the small moiety.
- 35 27. A hybridoma according to claim 23 which is selected by the reactivity of its culture fluid toward the small moiety or immunogen compound and its lack of

reactivity toward the corresponding carrier-spacer arm compound.

28. A hybridoma according to claim 23 which has
5 BioNebraska strain number 4A10B4 and ATCC deposit number ATCC HB10381, and wherein the small moiety is a mercury cation.
29. A hybridoma according to claim 23 which has
10 BioNebraska strain number 3H7G5, and ATCC deposit number ATCC HB10382 and wherein the metallic cation is lead.
30. A hybridoma according to claim 23 formed from fusion
15 of a murine, human or caprine myeloma cell line and the murine, lapin, equine, canine, feline, porcine or primate immune cells.
31. An immunogen compound comprising a protein carrier,
20 a spacer arm covalently bonded to the carrier and a small moiety coordinated in a substantially exposed state with the spacer arm, the small moiety being a metallic cation or an organic molecule having a molecular size of no more than about 15 atoms in
25 length.
32. An immunogen compound according to claim 31 wherein the organic molecule is a linear or branched aliphatic molecule or a small peptide.
30
33. An immunogen compound according to claim 31 wherein the spacer arm contains aromatic groups.
34. An immunogen compound according to claim 31 wherein
35 the small moiety is a metallic cation.

35. An immunogen compound according to claim 34 wherein the metallic cation is not a substantial physiological component of a mammal.
- 5 36. An immunogen compound according to claim 31 wherein the metallic cation is derived from a metal selected from the group consisting of aluminum, lithium, boron, gallium, gallenium, arsenic, period 4 transition metals, and period 5, 6 and 7 metals, transition elements and inner transition elements.
- 10 37. An immunogen compound according to claim 31 wherein the spacer arm is semi-rigid and has a small moiety coordination site arranged to maintain the small moiety in at least a partially exposed state.
- 15 38. An immunogen compound according to claim 31 wherein the spacer arm is an oligopeptide or aliphatic compound substituted with no more than about two pendent Lewis acid or base groups and a coupling group for forming a covalent bond with the protein carrier, or is an aliphatic fragment having a coupling group for forming a covalent bond with the protein carrier and being adapted for carbon-carbon bonding with, or covalently carbon bonded to the moiety when the moiety is an organic compound, said coupling group being an amino, carboxylic acid, hydroxyl, mercapto or aldehyde group, and said spacer arm being no more than about 25 atoms in length.
- 20 39. An immunogen compound according to claim 37 wherein the spacer arm has at least one coordination site for the small moiety.

40. An immunogen compound according to claim 39 wherein the spacer arm coordination with the small moiety is monodentate.
- 5 41. An immunogen compound according to claim 31 wherein the spacer arm is an oligopeptide or aliphatic compound substituted with no more than about two pendent Lewis base groups, the small moiety is a metallic cation, and the pendent Lewis base groups
10 are suitable for coordination with the metallic cation.
42. An immunogen compound according to claim 31 wherein the spacer arm is an aliphatic fragment of no more
15 than about six carbon atoms in length which is substituted by
 - (a) an amine, aldehyde, hydroxyl, mercapto or carboxylic acid group, and
 - (b) a coupling group for covalent bonding to
20 the carrier; and,
the small moiety is a organic molecule that is capable of forming a covalent bond with the amine, aldehyde, hydroxyl, mercapto or carboxylic acid group of the aliphatic fragment.
- 25 43. An immunogen compound according to claim 31 wherein the spacer arm is an oligopeptide, the small moiety is a metallic cation and the oligopeptide has pendent sulphydryl, amino or carboxy groups.
- 30 44. An immunogen compound according to claim 32 wherein the combination of the organic molecule and the spacer arm is glutathione.
- 35 45. A method for detecting a small moiety in liquid media, which comprises:

5 combining an aliquot of a liquid mixture suspected of containing the small moiety and an excess of immobilized or immobilizable antigen probe to produce a coordinated immobilized small moiety mixture;

10 combining the coordinated immobilized small moiety mixture and an excess of a monoclonal antibody of claim 1 to form a monoclonal antibody-antigen complex; and

15 determining the amount of monoclonal antibody-antigen complex present.

46. A method according to claim 45 wherein uncomplexed components are removed after the second combining step.

47. A method for detecting a small moiety in liquid, which comprises:

20 saturating a known first amount of an immobilized monoclonal antibody of claim 1 with a known amount of tagged small moiety to form a mixture containing a tagged monoclonal antibody-antigen complex;

25 removing all uncomplexed components from the mixture;

 adding an aliquot of an unknown second amount of small moiety to the mixture and allowing the resulting reaction to equilibrate; and

30 determining the concentration of unknown small moiety by measuring the amount of tag in solution after equilibration.

48. A method for detecting a first small moiety in liquid, which comprises:

35 adding an aliquot of the liquid suspected of containing the first small moiety to a known first

amount of immobilized antigen prob -second small moiety to form a first mixture;

5 adding a known second amount of a monoclonal antibody of claim 1 to the first mixture to form a complexed mixture, the second amount being less than sufficient for complexation with the entire first mixture;

10 removing all non-immobilized components from the complexed mixture to form a third amount of immobilized antigen probe-second small moiety-monoclonal antibody complex;

determining the amount of first small moiety in the aliquot by comparing the third amount and second amount; and

15 the monoclonal antibody being reactive with both the first small moiety and the antigen probe-second small moiety.

49. A method for detecting a small moiety in liquid,
20 which comprises:

placing a probe for the small moiety into an aliquot of the liquid, the probe being a high frequency oscillating means with monoclonal antibody of claim 1 immobilized thereon;

25 measuring the change in the oscillation rate; and

determining the concentration of small moiety as a function of the change.

30 50. A method for removing a small moiety from a liquid, which comprises:

adding an effective amount of monoclonal antibody of claim 1 to the liquid to form an immunoconjugate; and

35 removing the immunoconjugate from the liquid.

51. A method according to claim 50 further comprising combining an antigen probe with the effective amount of monoclonal antibody.
- 5 52. A method according to claim 50 wherein the removing step is accomplished by use of an immobilizable or immobilized substance that is capable of reacting with or binding to the monoclonal antibody.
- 10 53. A method according to claim 50 or 51 wherein the monoclonal antibody is immobilized.
54. A method for treating living cells with a small moiety, which comprises:
 - 15 administering to the living cells an effective amount of a complex of the small moiety and a monoclonal antibody of claim 1.
55. A method for combining a component and a small moiety, which comprises:
 - 20 adding a complex of the small moiety and a monoclonal antibody of claim 1 to a mixture containing the component wherein the monoclonal antibody is bifunctional and its second binding site is reactive with the component.
56. A method for detecting the presence of heavy metal ions in liquid medium which comprises:
 - 25 combining an immobilized or immobilizable antigen probe having coordinate sulfhydryl groups with an aliquot of the liquid medium suspected of containing heavy metal ions to form a coordinated immobilized heavy metal ion mixture;
 - 30 combining the coordinated immobilized heavy metal ion mixture an excess amount of a monoclonal antibody of claim 1 that binds with the heavy metal ions; and

determining the amount of monoclonal antibody heavy metal ion complex present.

57. A method according to claim 56 wherein uncomplexed
5 components are removed after the second combining
step.
58. A method for detection of a small moiety in liquid,
which comprises:
10 combining an aliquot of the liquid suspected of
containing the small moiety and excess amount of an
antigen probe to form an immobilized small moiety
mixture;
15 combining an excess amount of a monoclonal
antibody of claim 1 with the mixture to form an
immobilized complex;
20 adding an excess amount of a second antibody to
the immobilized complex to form a complexed mixture,
which second antibody is specific for all antibodies
produced by the mammal from which the monoclonal
antibody is derived;
removing all non-immobilized components from
the complexed mixture; and
25 determining the amount of second antibody-
monoclonal antibody complex present.
59. A method for detecting a small moiety in liquid
media which comprises:
30 adding an excess amount of a monoclonal
antibody of claim 1 to a liquid suspected of
containing the small moiety to produce an antibody-
antigen complex mixture;
35 combining the complex mixture with an excess
amount of immobilized antigen probe to form an
immobilized complex; and
determining the amount of the immobilized
complex present.

60. A method according to any of claims 45 through 59 wherein the probe is a spacer arm or a peptide or protein having a complexing group comprising a sulfhydryl, carboxyl carbonyl, hydroxyl or amino group or any combination thereof.
5
61. A fragment of a monoclonal antibody of any of claims 1 through 21.
10
62. A fragment according to claim 61 selected from the group consisting of an F_{ab} , an $F(ab)'$, a single light or heavy chain fragment, a mimetic variable region segment and a functional segment of the monoclonal antibody.
15
63. A fragment according to claim 61 which is produced by a recombinant DNA technique using a plasmid library containing a repertoire of DNA sequences taken from sensitized B cells.
20
64. A method according to any of claims 45 through 59 wherein a fragment of the monoclonal antibody is substituted for the monoclonal antibody.
25
65. A cocktail of monoclonal antibodies according to claim 1 which immunoreacts a group of different small moieties.
66. A purified class of polyclonal antibodies having high specificity for a group of small moieties with similar coordination chemistry and electron configuration and little cross-reactivity for other small moieties, which polyclonal antibodies are produced by immunizing a mammal with an immunogen compound comprising a protein carrier, a spacer arm covalently bonded to the carrier and the small
30
35

moiety coordinated in a substantially exposed state with the spacer arm.

67. A method for producing a hybridoma of claim 23
5 comprising:

immunizing a mammal with the immunogen compound to form sensitized immune cells in the mammal;

fusing the sensitized immune cells and immortal myeloma cells to form a group of hybridomas;

10 selecting a particular hybridoma from the group by testing the hybridoma culture fluid for a immunogenic response to the immunogen compound and for lack of cross-reactivity with the protein carrier and with the protein carrier-spacer arm
15 compound.

68. A method for producing an antibody of claim 1 or fragment thereof comprising:

20 causing a recombinant organism to express a library of antibodies or fragments encoded by inserted recombinant expression vectors containing the gene library for all antibodies or fragments thereof derived from the DNA of immune cells taken from a mammal sensitized with the immunogen
25 compound; and

selecting for the desired antibody or fragment thereof by testing the library of antibodies or fragments for immunogenic response to the immunogenic compound or a combination of antigen probe and small moiety and for lack of cross-reactivity with the protein carrier and with the protein carrier-spacer arm compound.




FIG. 1




FIG. 2




FIG. 3